MicroRNA in Lung Cancer Metastasis
AbstractTumor metastasis is a hallmark of cancer, with distant metastasis frequently developing in lung cancer, even at initial diagnosis, resulting in poor prognosis and high mortality. However, available biomarkers cannot reliably predict cancer spreading sites. The metastatic cascade involves highly complicated processes including invasion, migration, angiogenesis, and epithelial-to-mesenchymal transition that are tightly controlled by various genetic expression modalities along with interaction between cancer cells and the extracellular matrix. In particular, microRNAs (miRNAs), a group of small non-coding RNAs, can influence the transcriptional and post-transcriptional processes, with dysregulation of miRNA expression contributing to the regulation of cancer metastasis. Nevertheless, although miRNA-targeted therapy is widely studied in vitro and in vivo, this strategy currently affords limited feasibility and a few miRNA-targeted therapies for lung cancer have entered into clinical trials to date. Advances in understanding the molecular mechanism of metastasis will thus provide additional potential targets for lung cancer treatment. This review discusses the current research related to the role of miRNAs in lung cancer invasion and metastasis, with a particular focus on the different metastatic lesions and potential miRNA-targeted treatments for lung cancer with the expectation that further exploration of miRNA-targeted therapy may establish a new spectrum of lung cancer treatments. View Full-Text
Share & Cite This Article
Wu, S.-G.; Chang, T.-H.; Liu, Y.-N.; Shih, J.-Y. MicroRNA in Lung Cancer Metastasis. Cancers 2019, 11, 265.
Wu S-G, Chang T-H, Liu Y-N, Shih J-Y. MicroRNA in Lung Cancer Metastasis. Cancers. 2019; 11(2):265.Chicago/Turabian Style
Wu, Shang-Gin; Chang, Tzu-Hua; Liu, Yi-Nan; Shih, Jin-Yuan. 2019. "MicroRNA in Lung Cancer Metastasis." Cancers 11, no. 2: 265.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.